Tela Bio Inc
$ 0.84
0.56%
04 Mar - close price
- Market Cap 37,378,900 USD
- Current Price $ 0.84
- High / Low $ 0.92 / 0.82
- Stock P/E N/A
- Book Value 0.04
- EPS -0.83
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.39 %
- ROE -6.76 %
- 52 Week High 2.49
- 52 Week Low 0.67
About
TELA Bio, Inc., a medical technology company, focuses on the design, development and commercialization of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$3.45
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-11 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-12 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-09 | 2023-05-11 | 2023-03-21 |
| Reported EPS | -0.19 | -0.22 | -0.25 | -0.23 | -0.42 | -0.51 | -0.23 | -0.53 | -0.45 | -0.46 | -0.63 | -0.52 |
| Estimated EPS | -0.16 | -0.18 | -0.2075 | -0.222 | -0.4 | -0.47 | -0.5 | -0.43 | -0.49 | -0.53 | -0.56 | -0.55 |
| Surprise | -0.03 | -0.04 | -0.0425 | -0.008 | -0.02 | -0.04 | 0.27 | -0.1 | 0.04 | 0.07 | -0.07 | 0.03 |
| Surprise Percentage | -18.75% | -22.2222% | -20.4819% | -3.6036% | -5% | -8.5106% | 54% | -23.2558% | 8.1633% | 13.2075% | -12.5% | 5.4545% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TELA
2026-03-03 13:52:12
TELA Bio has launched the OviTex Reinforced Tissue Matrix, a new product aimed at supporting the regeneration of functional tissue. This advanced solution is now available through the company's website to improve patient outcomes in soft tissue repair. The introduction of OviTex reinforces TELA Bio's expanding role in regenerative medicine, meeting the growing demand for innovative surgical solutions.
2026-03-01 08:52:12
This article provides a detailed financial overview of Tela Bio, Inc. (TELA), including its income statement, balance sheet, cash flow statement, and key financial ratios. As of fiscal year 2024, the company reported $69.3M in revenue, reflecting 18.6% year-over-year growth, but remains unprofitable with a net income of -$37.8M. The analysis highlights mixed financial health, with strong liquidity but concerns regarding profitability, earnings quality, and interest coverage.
2026-02-26 08:52:12
TELA Bio, Inc. CEO Antony Koblish reported insider trading activity involving equity awards and tax-related share dispositions. He received 176,000 restricted stock units and a stock option for 261,000 shares, both with future vesting schedules contingent on his continued service. Additionally, he disposed of approximately 28,000 shares across several days in February 2026 to cover withholding taxes associated with RSU vesting.
2026-02-25 07:51:53
TELA Bio, Inc.'s President, Jeffrey Blizard, was granted 127,000 stock options and 86,000 restricted stock units (RSUs) on February 20, 2026. The RSUs will vest in four equal annual installments starting February 20, 2027, while the stock options vest 25% on February 20, 2027, with the remainder vesting monthly over the subsequent 36 months, all contingent on continued service. These awards represent equity compensation, and not open-market purchases.
2026-02-25 06:53:14
TELA Bio's COO and CFO, Roberto Cuca, received significant equity awards, including 85,000 stock options and 57,000 common shares as RSUs. The company also withheld 10,014 shares to cover tax obligations related to RSU vesting. Following these transactions, Cuca directly owns 257,377 shares of TELA Bio common stock.
2026-02-24 06:51:53
TELA Bio Inc. (NASDAQ: TELA) announced that its Compensation Committee approved inducement grants of restricted stock units (RSUs) covering 8,550 shares to three new employees. These grants, effective February 18, 2026, are part of their employment compensation and will vest annually over four years. This action aligns with Nasdaq Rule 5635(c)(4) for new hire inducements.
